Safety and Effectiveness of Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor, in Patients With Familial or Non-Familial Hypercholesterolemia　― A Post-Marketing Survey (J-POSSIBLE) ―-Reference-Cited by-同舟云学术

Safety and Effectiveness of Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor, in Patients With Familial or Non-Familial Hypercholesterolemia　― A Post-Marketing Survey (J-POSSIBLE) ―

Published:2023-05-25 Issue:6 Volume:87 Page:834-846
ISSN:1346-9843
Container-title:Circulation Journal
language:en
Short-container-title:Circ J

Author:

Kiyosue Arihiro¹,Yasuda Satoshi²,Tomura Akiyoshi³,Usami Makiko⁴,Arai Hidenori⁵

Affiliation:

1. Moriyama Memorial Hospital, Cardiovascular Center

2. Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine

3. General Medicines Medical, Sanofi

4. Post-Authorization Regulatory Studies, Sanofi

5. National Center for Geriatrics and Gerontology

Publisher

Japanese Circulation Society

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/circj/87/6/87_CJ-22-0445/_pdf

Reference25 articles.

1. 1. National Institute for Health and Clinical Excellence. Proposed health technology appraisal. Mipomersen for the prevention of cardiovascular events due to homozygous and severe heterozygous familial hypercholesterolaemia. 2011. https://www.nice.org.uk/guidance/gid-tag437/documents/hypercholesterolemia-mipomersen-appendix-b-draft-scope-for-consultation-prereferral-november-2011-2 (accessed February 25, 2022).

2. 2. Ibrahim MA, Asuka E, Jialal I. Hypercholesterolemia. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2022. https://www.ncbi.nlm.nih.gov/books/NBK459188/ (accessed November 18, 2022).

3. 3. Febriani D. The effect of lifestyle on hypercholesterolemia. Open Public Health J 2018; 11: 526–532.

4. 4. Japan Atherosclerosis Society. Familial hypercholesterolemia treatment guideline 2017 [in Japanese]. https://www.j-athero.org/jp/wp-content/uploads/publications/pdf/JAS_FH_GL2017.pdf (accessed March 30, 2022).

5. 5. Teramoto T, Kai T, Ozaki A, Crawford B, Arai H, Yamashita S. Treatment patterns and lipid profile in patients with familial hypercholesterolemia in Japan. J Atheroscler Thromb 2018; 25: 580–592.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of Alirocumab, Evolocumab, and Inclisiran in Patients with Hypercholesterolemia at Increased Cardiovascular Risk;Medicina;2024-07-12

2. No standard modifiable cardiovascular risk factors in acute myocardial infarction: prevalence, pathophysiology, and prognosis;Cardiovascular Intervention and Therapeutics;2024-06-17

3. Evaluation of proprotein convertase subtilsin /kexin 9(PCSK9) in serum of men hypertensive patients;CARDIOMETRY;2024-05-25

4. Identification of benzothiazoles as novel PCSK9 inhibitors;Bioorganic & Medicinal Chemistry Letters;2024-01